{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 40,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "CER = constant exchange rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/11",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.49,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "Comparison of February 2022 vs July 2022 guidance for Revenue and EPS",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c49b175a-ed25-405f-86db-30bb0cc374f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.46,
        "x": 0.52,
        "y": 0.31
      },
      "kind": "list",
      "text": "Total Revenue from COVID-19 medicines anticipated to be broadly flat vs. 2021; Core Operating Expense expected to increase by a mid-to-high teens percentage; Other Operating Income in H2 2022 expected to be broadly line with H1 2022; Emerging Markets Total Revenue expected to grow by mid-single digits; China Total Revenue expected to decline by a mid-single digit percentage; Core Tax Rate still expected to be between 18-22%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc7a849b-94cc-4d24-b087-631507bc3cb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.83
      },
      "kind": "paragraph",
      "text": "Growth supported by a diversified business model across key disease areas and geographies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0446dc9d-7255-4b8c-89c9-5b5d87304891",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.04,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "CER = constant exchange rates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e304229-2da6-40db-881f-57d1c6246c12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.73,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Overall business strength, improved COVID-19 medicines outlook",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4408f4ad-78be-47b7-9bb2-0dd3f0ca6ddd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.34,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "2022 guidance (CER)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cad29193-866f-41dd-bcb4-2a0422cd0348",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "2a571f32-10df-4fa4-8761-11900b08b42e",
      "evidence": "diagram/process: Comparison of February 2022 vs July 2022 guidance for Revenue and EPS",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}